PAP
RLAY icon

Persistent Asset Partners’s Relay Therapeutics RLAY Stock Holding History

Persistent Asset Partners’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-303
Closed -$9.85K – 227
2025
Q1 		$9.85K Hold
303
– – 0.01% 158
2024
Q4 		$24.2K Buy
+303
New +$1.65K 0.02% 124

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Persistent Asset Partners's RLAY Position: Q1 2026 in Review

Persistent Asset Partners opened a new position in Relay Therapeutics (RLAY) in Q1 2026: 16,358 shares worth $163K. The stake represents 0.06% of the portfolio and ranks #213 among its holdings. This is a return to the name: Persistent Asset Partners previously reported a position in RLAY as recently as Q3 2025.

Persistent Asset Partners first reported a position in RLAY in Q4 2024 and has held it in 5 quarters since. The position peaked at $652K in Q4 2024. 242 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

  • Persistent Asset Partners held 16,358 shares of Relay Therapeutics worth $163K as of Q1 2026.
  • Relay Therapeutics was a new Persistent Asset Partners position in Q1 2026.
  • Relay Therapeutics made up 0.06% of Persistent Asset Partners's portfolio in Q1 2026, its #213 holding.
  • Persistent Asset Partners first reported a position in Relay Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Persistent Asset Partners's Relay Therapeutics position peaked at $652K in Q4 2024.
  • 242 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.